Retatrutide vs Cagrilintide
Side-by-Side Comparison
| Attribute | Retatrutide | Cagrilintide |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / Amylin Analog |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon... | Cagrilintide activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and other hindbrain regions, promoting meal-related satiety through distinct pathways from GLP-1... |
| Evidence Rating | B — Phase III / NDA Filed | B — Phase III / NDA Filed |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | Phase 3 (REDEFINE program). NDA filed with FDA in 2026 for CagriSema. |
| Safety Profile | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) | GI adverse events: 79.6% in CagriSema group vs 39.9% placebo (nausea, vomiting, diarrhea, constipation); GI events mainly transient and mild-to-moderate |
| Route | Subcutaneous (clinical trial formulation only) | Subcutaneous |
| Dose Range | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 | Monotherapy: 1.2-4.5 mg weekly; CagriSema: fixed dose 2.4 mg cagrilintide + 2.4 mg semaglutide |
| Frequency | Once weekly | Once weekly |
| Molecular Weight | N/A | N/A |
| Half-Life | ~6 days (allows once-weekly dosing) | ~7 days (allows once-weekly dosing) |
Overview
Retatrutide and Cagrilintide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. In the Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), the 12 mg dose achieved 24.2% mean body weight reduction at 48 weeks, with 100% of participants achieving at least 5% weight loss. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Cagrilintide — Mechanism & Evidence
Cagrilintide is a long-acting synthetic analog of human amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. It is being developed by Novo Nordisk both as a standalone agent and in fixed-dose combination with semaglutide (CagriSema). The CagriSema combination targets complementary appetite pathways — amylin acts on hindbrain satiety circuits while GLP-1 acts on hypothalamic and gut pathways. In the REDEFINE Phase 3 program, CagriSema achieved 20.4% weight loss at 68 weeks. Novo Nordisk filed for FDA approval in 2026.
Key claims: CagriSema achieves ~20% weight loss; Superior to semaglutide alone; Standalone weight loss efficacy.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Retatrutide is also researched for: no additional unique applications.
Cagrilintide is also researched for: no additional unique applications.
Safety Considerations
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Cagrilintide: GI adverse events: 79.6% in CagriSema group vs 39.9% placebo (nausea, vomiting, diarrhea, constipation) GI events mainly transient and mild-to-moderate Similar safety profile to GLP-1 class: pancreatitis risk, gallbladder events, thyroid C-cell tumors in rodents
Related Products
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Related Research News
Retatrutide Clinical Trial Results: Phase III TRIUMPH Data Shows Significant Weight Loss
Early reports from the Phase III TRIUMPH-1 trial suggest retatrutide, a novel triple agonist, has delivered substantial weight loss outcomes. These retatrutide clinical trial results indicate a potential shift in obesity treatment research, though full data analysis is pending.
Retatrutide Phase III TRIUMPH-1 Results: Unprecedented Weight Loss Reported at ADA26
Early reports from the American Diabetes Association 2026 meeting suggest retatrutide delivered unprecedented weight loss in the Phase III TRIUMPH-1 trial. Researchers and industry professionals are closely watching these retatrutide clinical trial results for implications in obesity and metabolic disease treatment.
Cagrilintide-Semaglutide May Aid Type 2 Diabetes Glycemic Control
A combination of cagrilintide and semaglutide could improve glycemic control in patients with type 2 diabetes who are already using basal insulin, according to a report from Docwire News. The finding suggests a potential new treatment option for managing blood sugar levels in this patient population.